What You Ought to Know:
– Chronus Well being, a point-of-care diagnostics firm raises $22M in Sequence A funding led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor.
– Chronus intends to make use of the proceeds of the Sequence A financing to scale its analysis, engineering, and information science groups, along with accelerating the corporate’s product and know-how growth.
Diagnostics on Demand. Reimagined
Whereas many important indicators are simply obtained, the one take a look at that docs depend on to make 70% of their diagnoses—the blood take a look at—can take days for outcomes. Current blood analyzers are pricey, cumbersome, carry out restricted assessments, and require a educated lab technician for operation. Because of this, the one possibility has been to ship blood samples to a central lab for evaluation, introducing delays that may that negatively impression affected person care. Chronus Well being’s moveable in-vitro diagnostics (IVD) platform facilitates real-time blood diagnostics on the point-of-care, offering lab ends in minutes with the purpose of dramatically enhancing affected person outcomes. The system is designed to deal with roughly 85% of the blood assessments carried out yearly.
The Chronus Well being system is designed to ship real-time blood take a look at outcomes to healthcare suppliers, supplying them with instantly actionable information. By leveraging microfluidics and semiconductor know-how mixed with highly effective analytics utilizing information science instruments we’re redefining what is feasible in level of care blood testing.
“Our revolutionary platform is poised to disrupt the medical lab testing market, which primarily depends on costly and hulking blood analyzers in central labs,” explains Anand Parikh, CEO and co-founder of Chronus Well being. “Our low price and compact system, which leverages microfluidic and semiconductor applied sciences, permits real-time diagnostics in a number of medical settings and is designed to enhance time-to-care and outcomes for sufferers globally.”